neoplasm (MPN). The 2016 WHO diagnostic criteria for PV require identification of three major criteria or the first two major criteria and a minor criterion. 11 Major criteria are (i) increased hemoglobin level (>16.5 g/dL in men or >16.0 g/dL in women), increased hematocrit level (>49% in men or >48% in women), or other evidence of increased red cell volume >25% above normal; (ii) bone marrow biopsy showing hypercellularity for age with trilineage growth, and (iii) JAK2 V617F or JAK2 exon 12 mutations (present in >95% of PV patients). Subnormal serum erythropoietin level is considered a minor criterion. 11 In the USA, the latest estimation on PV prevalence was 44-57 cases per 100 000 person-years (py). 12 Incidence estimations of PV vary between 0.7 and 2.8 cases per 100 000 py. [13] [14] [15] [16] [17] No cure for PV is available. Current treatment options aim to prevent the occurrence of thrombotic or hemorrhagic events. These include low-dose aspirin and phlebotomy for low-risk patients and cytoreductive agents for highrisk patients: hydroxyurea (HU) or interferon alfa (IFN-α) as a first-line treatment. Of note, IFN-α is not reimbursed for treatment of PV in many European countries. Unfortunately, these treatments do not significantly improve symptom burden in all PV patients and patients can become resistant or intolerant to HU. 18 Furthermore, some evidence shows that PV patients who are resistant to HU have a higher risk of death and transformation to MF or AML. 19 Therefore, new therapies to address these unmet needs are in high demand.
Ruxolitinib, a new treatment alternative for patients resistant and/ or intolerant to HU, has shown promising results. In the RESPONSE phase III trial, 20.9% of PV patients (with splenomegaly) under ruxolitinib had hematocrit control and spleen size reduction in at least 35% after 32 weeks, vs 0.9% in the control group (receiving best-available therapy [BAT]). Forty-nine percent of the patients who received ruxolitinib (vs 5% of the patients in the control group) had at least a 50% reduction in the MPN-SAF total symptom score. The number of reported thrombotic events was lower in the ruxolitinib group. 20 After 80 weeks, 89% of patients maintained the hematological response they obtained at week 32. 21 The RESPONSE-2 study evaluated the efficacy and safety of ruxolitinib vs BAT in HU-resistant or intolerant PV patients with nonpalpable spleen. Patients treated with ruxolitinib maintained hematocrit control without the need for phlebotomy. 22 Ruxolitinib was generally well tolerated by PV patients. The occurrence and severity of adverse events was similar in patients receiving ruxolitinib or best-available therapies. [20] [21] [22] Moreover, long-term follow-up of patients treated with ruxolitinib did not reveal progressively worsening toxicity. 21 The objective of the present scientific survey was to gather predefined disease parameters from Belgian patients with PV to better understand the disease characteristics, the currently used treatment strategies, and the proportion of patients that may benefit from new promising treatment options. 
| METHODS
A scientific survey was designed to collect data on Belgian PV pa- The analysis of the collected information was descriptive and quantitative. No formal statistical analysis plan was set out; neither has any statistical hypothesis been formulated.
| RESULTS

| Disease characteristics
Data from a total of 343 patients with PV were collected. Of these, 174 (50.7%) were male and 256 (74.6%) were older than 60 years of age. Ninety-two patients (26.8%) had a history of thrombotic event(s).
The mean age of the patients enrolled in the survey was 67.3 years, and the mean time since PV diagnosis was 7.4 years ( The majority of patients (284, 87.7%) had a non-palpable spleen.
Thirty-eight (11.7%) patients had a palpable spleen, and 2 (0.6%) patients were splenectomized (Table 1) ≥47%-<50%, and 22 (6.5%) ≥50%.
| Current treatment strategies
The majority of patients (315, 91.8%) received thrombosis prophylaxis, among which 249 (72.6%) received low-dose aspirin and 66 The majority of patients were assessed by the treating physicians as neither intolerant nor resistant to HU (247, 72.2%), and 54 patients (15.8%) were never exposed to HU. A total of 41 patients (12.0%)
were assessed by the treating physicians as either HU-resistant, HU- 
| DISCUSSION
Data from 343 Belgian PV patients were collected by this survey, with an approximatively 1:1 gender ratio, a mean age of 67.3 years, and a mean time since diagnosis of 7.4 years. The age distribution of participants is comparable to those reported in other PV studies. 5, 12, 14, 15 A considerable proportion of patients were at high risk for thrombosis (81.1%), and at high risk for shortened survival (67.6%).
The majority of patients had a non-palpable spleen (87.7%), similar to what was seen in a recent observational study in Spain (~84%). About a quarter of the participating patients (26.8%) had a previous thrombotic event, which is also similar to the 24% proportion reported in the Spanish study. 24 The proportion of PV patients receiving thrombosis prophylaxis in this study (91.8%) is also consistent with other studies, where up to 90% of PV patients received this treatment. 10, [25] [26] [27] About half of the patients included in our survey (57.4%) did not require any phlebotomy within the last 6 months, while the rest received 1 or more: 1-2 phlebotomies for 69 patients (20.1%), 3-4 phlebotomies for 52 patients (15.2%), and 5-6 phlebotomies for 21 patients (6.1%); 4 patients (1.2%) had more than 7 phlebotomies.
Although phlebotomies are a crucial and unique treatment choice in PV patients to obtain a fast decrease in the hematocrit when necessary (often at diagnosis), repeated phlebotomies are not always well tolerated by patients. 28 In our study population, the majority of patients (232 of HU-treated patients reported rates similar to those in our study for hematocrit >45% (34.4%), but higher rates for platelet >400 × 10 9 /L (59.4%) and WBC >10 × 10 9 /L (58.2%) counts. 29 The large proportion of PV patients with higher than recommended (>45%) hematocrit values in our survey may be explained by insufficient knowledge of existing treatment guidelines or by HU intolerance, limiting its dosage in the absence of adequate alternatives.
Another explanation for this observation might be that these patients are less adherent to the prescribed HU regimen than perceived by their physicians.
The majority of patients (72.2%) were assessed by the treating physicians as not intolerant or resistant to HU, and 15.8% were never exposed to HU. Twelve percent of the patients were assessed by the investigators as being HU-resistant and/or intolerant. Comparing their hematological measurements with the ELN criteria for HU resistance and intolerance 23 suggests that the 12.0% value is an underestimation.
The difference between HU resistance/intolerance as assessed by the investigators and HU resistance/intolerance as per the ELN criteria shows that the strict ELN criteria for HU resistance and intolerance are not often used in the clinical "real-life" practice and are probably not well known.
Limitations of our study include the fact that these parameters
were not captured over a period of time, but rather at one time point, and that HU dosage or treatment duration information was not collected, nor could the study distinguish between inadequately treated and truly HU-resistant patients. Such data could have provided more insight regarding the response of Belgian PV patients to HU treatment.
In Phase II and III trials, ruxolitinib, a JAK1, and JAK2 inhibitor showed consistent clinical benefit in PV patients intolerant/resistant to HU. [20] [21] [22] 30 Based on these findings, ruxolitinib was approved They also suggest that a large group of PV patients continues to receive HU despite being potentially resistant. Besides the fact that a combination of low-dose HU and phlebotomies is often well tolerated by patients, the absence of second-line treatment options is probably one of the main reasons why these patients continued to receive HU, as neither ruxolitinib or interferons were reimbursed in Belgium for the treatment of PV patients at the time of data collection.
